Biomarker Tests for Molecularly Targeted Therapies: Key to Unlocking Precision Medicine | Agenda Bookshop Skip to content
Selected Colleen Hoover Books at €9.99c | In-store & Online
Selected Colleen Hoover Books at €9.99c | In-store & Online
A01=and Medicine
A01=Board on Health Care Services
A01=Committee on Policy Issues in the Clinical Development and Use of Biomarkers for Molecularly Targeted Therapies
A01=Engineering
A01=Institute of Medicine
A01=National Academies of Sciences
Age Group_Uncategorized
Age Group_Uncategorized
Author_and Medicine
Author_Board on Health Care Services
Author_Committee on Policy Issues in the Clinical Development and Use of Biomarkers for Molecularly Targeted Therapies
Author_Engineering
Author_Institute of Medicine
Author_National Academies of Sciences
automatic-update
B01=Harold L. Moses
B01=Jonathan K. Phillips
B01=Laurene A. Graig
Category1=Non-Fiction
Category=MFN
COP=United States
Delivery_Delivery within 10-20 working days
Language_English
PA=Available
Price_€50 to €100
PS=Active
softlaunch

Biomarker Tests for Molecularly Targeted Therapies: Key to Unlocking Precision Medicine

Every patient is unique, and the evolving field of precision medicine aims to ensure the delivery of the right treatment to the right patient at the right time. In an era of rapid advances in biomedicine and enhanced understanding of the genetic basis of disease, health care providers increasingly have access to advanced technologies that may identify molecular variations specific to an individual patient, which subsequently can be targeted for treatment. Known as biomarker tests for molecularly targeted therapies, these complex tests have the potential to enable the selection of the most beneficial treatment (and also to identify treatments that may be harmful or ineffective) for the molecular underpinnings of an individual patient's disease. Such tests are key to unlocking the promise of precision medicine.

Biomarker tests for molecularly targeted therapies represent a crucial area of focus for developing methods that could later be applicable to other areas of precision medicine. The appropriate regulatory oversight of these tests is required to ensure that they are accurate, reliable, properly validated, and appropriately implemented in clinical practice. Moreover, common evidentiary standards for assessing the beneficial impact of biomarker-guided therapy selection on patient outcomes, as well as the effective collection and sharing of information related to those outcomes, are urgently needed to better inform clinical decision making.

Biomarker Tests of Molecularly Targeted Therapies examines opportunities for and challenges to the use of biomarker tests to select optimal therapy and offers recommendations to accelerate progress in this field. This report explores regulatory issues, reimbursement issues, and clinical practice issues related to the clinical development and use of biomarker tests for targeting therapies to patients. Properly validated, appropriately implemented biomarker tests hold the potential to enhance patient care and improve outcomes, and therefore addressing the challenges facing such tests is critical.

Table of Contents
  • Front Matter
  • Summary
  • 1 Introduction
  • 2 Envisioning a Rapid Learning System for Biomarker Tests for Molecularly Targeted Therapies
  • 3 Supportive Policy Environment for Biomarker Tests for Molecularly Targeted Therapies
  • 4 Supporting Data Infrastructure for Biomarker Tests for Molecularly Targeted Therapies
  • 5 Processes to Improve Patient Care
  • Appendix A: Committee Member and Staff Biographies
  • Appendix B: Coding: Payment Infrastructure for Biomarker Tests for Molecularly Targeted Therapies
  • Appendix C: Information-Gathering Sessions and Speakers
  • Glossary
See more
Current price €61.74
Original price €64.99
Save 5%
A01=and MedicineA01=Board on Health Care ServicesA01=Committee on Policy Issues in the Clinical Development and Use of Biomarkers for Molecularly Targeted TherapiesA01=EngineeringA01=Institute of MedicineA01=National Academies of SciencesAge Group_UncategorizedAuthor_and MedicineAuthor_Board on Health Care ServicesAuthor_Committee on Policy Issues in the Clinical Development and Use of Biomarkers for Molecularly Targeted TherapiesAuthor_EngineeringAuthor_Institute of MedicineAuthor_National Academies of Sciencesautomatic-updateB01=Harold L. MosesB01=Jonathan K. PhillipsB01=Laurene A. GraigCategory1=Non-FictionCategory=MFNCOP=United StatesDelivery_Delivery within 10-20 working daysLanguage_EnglishPA=AvailablePrice_€50 to €100PS=Activesoftlaunch
Delivery/Collection within 10-20 working days
Product Details
  • Dimensions: 152 x 229mm
  • Publication Date: 30 Jul 2016
  • Publisher: National Academies Press
  • Publication City/Country: United States
  • Language: English
  • ISBN13: 9780309381345

Customer Reviews

Be the first to write a review
0%
(0)
0%
(0)
0%
(0)
0%
(0)
0%
(0)
We use cookies to ensure that we give you the best experience on our website. If you continue we'll assume that you are understand this. Learn more
Accept